USA flag logo/image

An Official Website of the United States Government

MyNutritionPlanner: Development and Evaluation of an Innovative Software…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43NS083230
Solicitation Year:
2013
Solicitation Topic Code:
NINDS
Solicitation Number:
PA12-088
Small Business Information
BIOSTRATEGIES, LC
P.O. BOX 2428 STATE UNIVERSITY, AR 72467-2428
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: MyNutritionPlanner: Development and Evaluation of an Innovative Software Approach
Agency: HHS
Contract: 1R43NS083230-01
Award Amount: $285,783.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of this proposal is to develop an effective enzyme replacement therapy (ERT) for Sanfilippo A patients by exploiting safety, supply, and cost advantages of plant-based enzyme bioproduction while integrating novel ERT delivery strategies being development at BioStrategies LC. Sanfilippo A (MPS-IIIA) is a rare genetic lysosomal storage disorder affecting less than 200,000 people in the U.S. It is caused by a defect in the gene encoding the enzyme heparin N-sulfatase (SGSH) and is characterized by progressive degeneration in normal childhood development especially in brain function leading to death at an early age. Current treatment options are limited to symptom management and development of an effective ERT drug has been hindered by challenges of delivering these drugs to the brain and central nervous system (CNS). The promise of plant-made bioproduction has recently been recognized with the FDA approval of Elelyso (taliglucerase), Protalix/Pfizer's plant-made glucocerebrosidase ERT for Gaucher Disease. If successful, this SBIR will lead to an effective ERT-based treatment for Sanfilippo A patients, a patient population with desperate need and limited options. Utilizing BioStrategies' new plant lectin-ERT fusion and delivery technology to be further developed during this project, this research will lead to a fundamental paradigm shift for ERT-based treatment approaches based on innovative alternate cell targeting mechanisms, mucosal delivery, and trans-blood-brain-barrier (BBB) activity. The potential for a marketable product is very high. With the recent FDA approval of plant-made Elelyso and industry showing elevated interest in rare disease targets and lowering drug development and production cost/timelines, thesenew technologies for plant-based bioproduction are highly competitive. Independent of the lectin delivery aspects, plant-derived SGSH will bring cost and safety advantages over mammalian cell-derived SGSH ERT. If the promise of lectin- mediated ERT delivery is met, lectin:SGSH fusions would be a treatment of choice for MSP-IIIA and this drug delivery technology could be broadly developed to target other diseases with strong CNS involvement or indications for transmucosal delivery. This Phase I project will address the following specific questions: a) Are plants capable of producing bioactive human heparin sulfatase (SGSH)?, b) Can SGSH - plant lectin fusions be produced that retain both SGSH enzyme activity and carbohydrate binding selectivity?, and c) Arethese plant-made proteins delivered to and corrective in in vitro Sanfilippo A cell models. Success in Phase I will demonstrate the feasibility of plant-based bioproduction of bioactive SHSG and the lectin-fusion ERT with SGSH and will support subsequentPhase II studies to further product characterization, scaled-up production to support animal trials, in vivo disease correction and ERT efficacy studies in MSP-IIIA mouse models, and assessment of BBB transcytosis and CNS disease substrate clearance.PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The family of human genetic diseases represented by the lysosomal storage disorders (LSDs) and Sanfilippo A Syndrome include some of the most devastating afflictions known and the most costly to patients, their families and the public health system. Currently available enzyme replacement therapeutics (ERTs), although effective for many patients, suffer from problems of safety, high cost, product effectiveness, availability of adequate product suppliesto patient populations, and patient inconvenience of current IV treatment options. The new therapeutics technologies developed in this SBIR Phase I RandD project would address all of these issues by employing more convenient mucosal delivered ERT products(e.g. by inhalation), which are more effectively targeted to affected cell types and compartments, and are safer and cheaper to supply to patient populations by virtue of employing newer plant-based production technologies. The innovative drug delivery technology developed in this project would further the goal of reducing the cost and suffering of patients afflicted with these devastating genetic diseases.

Principal Investigator:

David Radin
870-897-7310
radin@biostrategies-lc.com

Business Contact:

David N. Radin
870-897-7310
radin@biostrategies-lc.com
Small Business Information at Submission:

BIOSTRATEGIES, LC
P.O. BOX 2428 STATE UNIVERSITY, AR 72467-2428

EIN/Tax ID: 127000024
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No